



**Strategy and Sustainability Division**  
**MINISTRY FOR HEALTH, THE ELDERLY AND COMMUNITY CARE**

**DH CIRCULAR No.51/2011**

**DH 914/2011**

23<sup>rd</sup> February, 2011

**Attention all** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Clopidogrel tablets, 75 mg**

Clopidogrel tablets, 75 mg have been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for the introduction into the Government Formulary List. Consultant Cardiologists, and Cardiac Surgeons can prescribe Clopidogrel tablets, 75 mg in combination with aspirin, in patients suffering from Non-ST segment elevation acute coronary syndrome and undergoing a stent placement following percutaneous coronary intervention (PCI). The Clopidogrel tablets, 75 mg will replace ticlopidine for this particular indication. Clopidogrel tablets, 75 mg is protocol-regulated and the protocol number is 276 (attached).

Clopidogrel tablets, 75 mg have been procured through GHPS and are now available for use as per protocol.

Clopidogrel tablets, 75 mg will only be dispensed for 1 month against a Protocol-regulated request that is according to protocol, until the actual approval is issued. For continuity of treatment, a valid approval is required.

Thank you

For your attention, please

Dr Natasha Azzopardi Muscat

Director General

## **Clopidogrel 75mg tablets**

**Prescriber Criteria:** Consultant Cardiologist  
Consultant Cardiac Surgeon

**Schedule V Condition:**

1. Ischaemic Heart Disease

**Clinical Indications qualifying patients for treatment:**

In combination with aspirin, in patients suffering from Non-ST segment elevation acute coronary syndrome and undergoing a stent placement following percutaneous coronary intervention:

- Loading dose: a single dose of 300mg initially
- Maintenance dose: 75mg once a day
- Duration of treatment: **up to 12 months**

**Duration of approval:**

1 year